For example, CNIH4 and CRIP2 acted as inhibitors of GS progression in the ST analysis, but the expression of both genes was upregulated in the most advanced stages of TCGA-PRAD (in the GS > 7, pT3, TP53 mutation, and HR > 1 in survival analysis of RFS and PFS) (Table S7). This evidence concerns the gene TP53 and prostate adenocarcinoma.